G
157.68
-3.82 (-2.37%)
| Previous Close | 161.50 |
| Volume | 504,107 |
| Price / Sales | 17.62 |
| Price / Book | 55.67 |
| 52 Weeks Range |
| Profit Margin | -53.82% |
| Operating Margin (TTM) | -54.33% |
| Diluted EPS (TTM) | -3.39 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -272.26 M |
| Levered Free Cash Flow (TTM) | -67.71 M |
| Return on Assets (TTM) | -18.64% |
| Return on Equity (TTM) | -4,584.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Guardant Health, Inc. | Mixed | Bullish |
AIStockmoo Score
0.0
| Analyst Consensus | NA |
| Insider Activity | 0.0 |
| Price Volatility | -1.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | 0.00 |
|
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 4.53% |
| % Held by Institutions | 97.57% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |